MSB 1.01% 98.0¢ mesoblast limited

The Lvad trial has Rmat designation which is similiar to...

  1. 188 Posts.
    lightbulb Created with Sketch. 133
    The Lvad trial has Rmat designation which is similiar to breakthrough status.
    A trial that passes phase one with sufficient safety and the chances of efficacy can be approved by FDA
    There will be follow up in either one of a confirming trial, following real world cases or both
    Check out RMAT guidlines
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
98.0¢
Change
-0.010(1.01%)
Mkt cap ! $1.118B
Open High Low Value Volume
$1.00 $1.01 98.0¢ $4.720M 4.751M

Buyers (Bids)

No. Vol. Price($)
10 171759 98.0¢
 

Sellers (Offers)

Price($) Vol. No.
99.0¢ 16000 1
View Market Depth
Last trade - 16.10pm 25/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.